Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Meet with Modular Medical CEO, Jeb Besser There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.100% of patient population require daily insulin i
TAMPA, Fla. , Sept. 4, 2024 /PRNewswire/ -- Integrated Ventures Inc. (OTCQB: INTV), a holdings company, focused on e-commerce technology, digital assets and consumer-focused investments, is excited to
4 Stocks That Boosted Their Bottom Line with Beef
07:29am, Wednesday, 04'th Sep 2024
The advent of GLP-1 weight-loss treatments has inadvertently underscored the importance of protein in mitigating muscle loss. While taking GLP-1 meds may be out of reach of many consumers due to exorb
3 GLP-1 Stocks to Buy Now For Big Long-Term Gains
09:12am, Sunday, 01'st Sep 2024
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive.
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
06:32am, Friday, 30'th Aug 2024
Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations. Despite com
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Weight Loss
10:30am, Wednesday, 28'th Aug 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 28, 2024) - Investorideas.com, a go-to investing platform covering health and wellness and biotech stocks issues a snapshot lo
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products
08:43am, Wednesday, 28'th Aug 2024
TAMPA, Fla. , Aug. 28, 2024 /PRNewswire/ -- Integrated Ventures, Inc. (OTCQB: INTV), a diversified portfolio holdings company, is excited to announce its strategic entry into the rapidly expanding he
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
07:30am, Wednesday, 28'th Aug 2024
In conjunction with this new offering, 23andMe, Lemonaid Health's parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s In conjuncti
Why Eli Lilly is a top GLP-1 stock: Roundhill CEO
07:42pm, Tuesday, 27'th Aug 2024
Pharmaceutical companies have significantly grown over the last year as demand for GLP-1 weight-loss drugs continues to skyrocket. Roundhill Investments CEO Dave Mazza joins Market Domination for the
First Results from Lexaria's Second GLP-1 Human Pilot Study
09:20am, Tuesday, 27'th Aug 2024
Trend toward higher overall absorption under fed conditions evidenced with DehydraTECH®-processed Rybelsus® KELOWNA, BC / ACCESSWIRE / August 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
12:00pm, Monday, 26'th Aug 2024
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contender
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
08:00am, Friday, 23'rd Aug 2024
Eli Lilly and Novo Nordisk's top diabetes drugs each brought in more than $3 billion in sales last quarter. Ozempic has been on the market for longer, but its growth rate isn't as impressive as that o
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
09:20am, Thursday, 22'nd Aug 2024
DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide Select DehydraTECH-CBD formulations appear to continue to outperform DehydraTECH-semaglutide KELOWNA, BC / ACCESSWIRE / August 22, 2024
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
07:00am, Thursday, 22'nd Aug 2024
CBeyond™ will assess nimacimab's ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab CBeyond™ will assess nimacimab's ability to s
Viking Therapeutics could be a new winner in the GLP-1 space
05:30pm, Wednesday, 21'st Aug 2024
GLP-1 weight-loss drugs have taken the pharmaceutical world by storm, Novo Nordisk (NVO) and Eli Lilly (LLY) making a name for the class of drugs through their own landmark brands. But what about the
